Can Ascletis Pharma challenge injectable GLP-1 leaders with oral ASC30?
Oral GLP-1s promise convenience, but proof is still clinical. Ascletis’ ASC30 diabetes trial could test whether hype can meet HbA1c data.
Sciwind Biosciences and Pfizer China bet on ecnoglutide as China’s GLP-1 market enters its most competitive phase
Sciwind Biosciences partners with Pfizer China on ecnoglutide. Explore what this GLP-1 deal changes for obesity, diabetes, and China’s drug market.
Is DOXA the multi-mechanism small molecule NewcelX needs for narcolepsy and ALS?
NewcelX Ltd. has announced the publication of its international DOXA compound patent in China, further securing intellectual property protection for its cross-domain pipeline in neurology and metabolic diseases. The patent application covers a new class of small molecules derived from quinazoline, benzothiazine, and benzoxazine scaffolds. These compounds are designed to modulate orexin signaling, neuroinflammation, and […]